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Background: Rheumatic mitral valve disease is a common disease
in India. Even in the presence of preserved global LV function as
measured by EF, in some RHD patients, impairment in long-axis
function can occur early. Recently Impaired LV long- axis move-
ment (by TDI) & myocardial strain is sensitive indicator of early
myocardial dysfunction.
Aims and objectives: (1) To study TDI and its application in patients
of Rheumatic MV disease. (2) To study the tissue Doppler velocities
at the MV annulus. (3) To evaluate LV function in patients of
rheumatic MV disease using strain& strain rate imaging.
Material and methods: This is single center prospective observa-
tional study conducted in 50 patients (pts) with rheumatic MSwith
orwithoutMRwith sinus rhythm in addition to 50 controls (cls). Pts
with predecided inclusion& exclusion criteria were enrolled in this
study & echo was done tomeasure MPI (tie) index, TD velocities (at
the lateral MV annulus), Peak systolic myocardial velocity (Sm),
Early diastolic velocity (Em) & strain imaging (SI) measured from
averaged value of 6 LV segments from apical 4-C view.
Results: In this study mean age was 29.94  8.02 in pts and 33.18
 9.0 in cls. Mean EF was 57.98  2.527 in pts & 58.74  2.783 in cls
(p-.15). MeanMPI by TDIwas 4560  .02740 in pts & 3934  .03543 in
cls ( p < .0001). Mean Sm was 7.98  1.152 in pts & 13.44  1.740 in
cls ( p < .0001). Mean Em was 8.70  1.689 in pts & 16.18  1.945 in
cls ( p < .0001). Mean averaged peak sys strainwas 17.7820  1.1182
in pts& 21.9384  1.431 in cls ( p < .0001). Mean averaged strain rate
was 0.893  0.855 in pts & 1.455  0.142 in cls ( p < .0001).
Conclusion: Using TDI, our study revealed that the MPI was sig-
niﬁcantly increased in pts compared to control group. Moreover
Sm, Em velocity and peak strain and strain rate was signiﬁcantly
lower in patients compared to control group. Thus MPI, Sm & Em
velocity and strain imaging can be useful in the detection of
subclinical LV dysfunction in patients of rheumatic MV disease.
Use of tenecteplase in treatment of
thrombotic prosthetic mitral valves
Ashish Amladi *, B. Kapoor, M. Jain, S. Shivpuje
11-B-1, Embee Apartments, Saibaba Nagar, Borivli West, Mumbai
400092, India
Introduction: Prosthetic valve thrombosis is deﬁned as any
obstruction of the prosthesis by non-infective thromboticmaterial.
The diagnosis of PVT is made by a combination of clinical data
(sudden worsening of heart failure, absence of prosthetic valve
sounds, pulmonary edema, cardiogenic hock) and echocardiogra-
phy. PVT is a life threatening emergency and requires treatment at
the earliest. Reported incidence of thrombosis of prosthetic mitral
valve is 0.03–4.3% per year. Thrombectomy or valve replacement is
the conventional treatment with an associated mortality rate of
4.7–20%.
Thrombolysis is emerging as a promising alternative to surgery
with a success rate ranging from 75% to 83%. In recent years,
thrombolytic therapy has evolved as a substitute to surgery. Var-
ious thrombolytic treatments have been reported with variable
success rates including streptokinase, urokinase and recombinant
tissue plasminogen activators. Most patients in published series
have been treated with infusions of streptokinase or urokinase for
12–24 hours. However, the data on the use of tenecteplase (a
synthetic tissue plasminogen activator) is limited.
It has been used extensively in acutemyocardial infarction (includ-
ing in our institute) but its use in PVT treatment has rarely been
reported.
Aims and objectives: To study the efﬁcacy and safety of
single intravenous bolus administration of tenecteplase in the
management of patients presenting with thrombosis of prosthetic
mitral valves in comparison to the use of streptokinase.
Materials and methods: All patients who presented with symp-
toms, clinical ﬁndings and radiological reports suggestive of
thrombosis of prosthetic mitral valves and who were not willing
to undergo emergency mitral valve replacement were included in
this study. Patients who had contraindications to thrombolysis
were excluded.
Patients were offered both streptokinase and tenecteplase, choices
differed as per ﬁnancial constraints.
All consecutive patients presenting with thrombosis of prosthetic
mitral valve, in NYHA Class III/IV were included in study if they
were not willing to undergo emergency mitral valve replacement.
The diagnosis of thrombosis of prosthetic mitral valves was estab-
lished mainly by trans-thoracic or trans-esophageal echocardio-
graphy and/or ﬂuoroscopy.
Patients with contraindication for thrombolytic therapy were
excluded from the study (i.e., previous haemorrhagic stroke or
other stroke within one year or known intracranial neoplasm or
Active internal bleeding -excluding menses or suspected aortic
dissection).
The ﬁbrinolytic agent used was tenecteplase given in weight
adjusted dose. Fibrinolytic regimens used were streptokinase
and tenecteplase, 0.5 mg/kg IV bolus administered over 5 s.
Heparin infusion was usually introduced after ﬁbrinolytic ther-
apy. Heparin infusion to obtain a partial thromboplastin time
between 70 and 90 s was continued for one week and then
replaced by warfarin treatment adjusted to obtain optimal pro-
thrombin time and international normalized ratio. The efﬁcacy of
ﬁbrinolytic therapywas assessed fromhemodynamic parameters
derived from echographic examinations as well as on clinical
grounds.
We deﬁned success as:
 Full: hemodynamic normalization conﬁrmed by cineﬂuoro-
scopy (normal mobility of tilting disks) or TTE/TEE data
(normalization of transprosthetic gradient and valve area,
normal mobility of leaﬂet, reappearance of click).
 Incomplete: signiﬁcant clinical improvement without com-
plete recovery of disc or leaﬂetmotion onﬂuoroscopy and/or
TTE.
 Failure: no clinical improvement, in many cases associated
with death or complications.
Results: Complete resolution of hemodynamic abnormalities was
seen in 13/13 patients who received tenecteplase while 16 out of
eighteen patients had complete resolutionwith streptokinase. One
patient had failure of therapy and succumbed to pulmonary edema
and another had partial resolution.
In patients who received tenecteplase, symptoms improvedmark-
edly, and prosthetic-valve clicks reappeared after a mean (SD)
period of 67.5  29 minutes (within 30 min in two patients).
No hemorrhagic complications were observed in any patients.
Two documented embolic event occurred during ﬁbrinolytic ther-
apy. (Brachial artery embolism, requiring embolectomy and stroke
due to embolism.)
None of the patients required subsequent surgery, and all were
alive and well after treatment and discharged in a stable condition
on warfarin in 7–10 days.
Treatment of patients with thrombosis of a prosthetic valve
remains controversial.
Our results in thirteen consecutive patients suggest that tenecte-
plase can be used safely in patients with prosthetic-valve throm-
bosis, resulting in rapid restoration of valve function as compared
the conventionally used streptokinase, beside ease of administra-
tion, i.e., bolus verses prolonged infusion.
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